Società Northwest Biotherapeutics, Inc. Other OTC
Azioni
NWBO
US66737P6007
Biotecnologia
Attività
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Innovative Immunotherapies for Cancer
100,0
%
| 2 | 100,0 % | 2 | 100,0 % | +14,80% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States, Germany, United Kingdom and Netherlands
100,0
%
| 2 | 100,0 % | 2 | 100,0 % | +14,80% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Linda Powers
CEO | Chief Executive Officer | 68 | 17/05/07 |
Alton Boynton
FOU | Founder | 79 | 18/03/96 |
Marnix Bosch
CTO | Chief Tech/Sci/R&D Officer | 65 | 01/01/00 |
David Innes
IRC | Investor Relations Contact | - | 26/02/19 |
Leslie Goldman
LAW | General Counsel | 78 | 01/06/11 |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Alton Boynton
FOU | Founder | 79 | 18/03/96 |
Linda Powers
CEO | Chief Executive Officer | 68 | 17/05/07 |
Navid Malik
BRD | Director/Board Member | 55 | 01/04/12 |
Joseph Black
BRD | Director/Board Member | 74 | 27/01/16 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 0 | 1 300 000 | 0 | 0 | 90,84 % |
Azione B | 1 | 1 210 879 427 | 1 099 989 992 ( 90,84 %) | 0 |
Coordinate società
Northwest Biotherapeutics, Inc.
4800 Montgomery Lane Suite 800
20814, Bethesda
+240 497 9024
http://www.nwbio.comSettore
Variaz. 1 gen. | Capi. | |
---|---|---|
+16,49% | 122 Mrd | |
+21,73% | 115 Mrd | |
+22,88% | 26,64 Mrd | |
-21,81% | 19,91 Mrd | |
-16,75% | 16,32 Mrd | |
-18,81% | 15,49 Mrd | |
-44,74% | 15,52 Mrd | |
+62,72% | 14,83 Mrd | |
+3,09% | 13,67 Mrd |